McDermott + Bull has successfully placed Lisa Henry as Vice President, Clinical and Regulatory at Magenta Medical. Reporting to the CEO, Lisa will lead the clinical and regulatory strategies critical to Magenta’s success. As the first U.S.-based team member, Lisa will be instrumental in building out the clinical program, setting up the Pivotal Trial, and guiding the company through essential regulatory pathways to bring Magenta’s innovative products to market. In this dual role, her leadership will play a vital role in expanding the company’s footprint into the U.S.
Lisa brings over 18 years of experience in clinical and regulatory affairs, with a proven track record in global clinical trial management and regulatory strategy. Prior to joining Magenta Medical, Lisa held leadership positions at Edwards Lifesciences, where she was instrumental in driving clinical trial success and ensuring data integrity for global submissions. Her previous experience includes key roles at Cordis Corporation and AngioScore, where she managed complex clinical programs and established crucial regulatory pathways. Lisa is a registered nurse and holds certification from the Regulatory Affairs Professional Society (RAPS) as a U.S. RAC since 2012.
Magenta Medical is dedicated to pioneering innovations in cardiovascular solutions, with a focus on advancing medical technologies that meet significant patient needs. The company’s mission centers on developing transformative products with a strong commitment to quality and regulatory compliance.
This executive search was completed by McDermott + Bull Partner Ken Dropiewski, Director Shelby Varon, and Research Associate Michael Matranga.